TIGOFAST WINS AN AWARD IN THE NOMINATION "OPTIMAL COMPLIANCE IN THE CHOICE OF ANTIHISTAMINE THERAPY"
On December 17, 2021, within the framework of the Expert Version project, an online conference was held with the support of the Association of Allergists of Ukraine
Leading Ukrainian experts in the field of otolaryngology and allergology presented their reports on the peculiarities of therapy for patients with allergic pathology. More than 1,700 doctors from all over Ukraine took part in the conference.
The report Experience of using antihistamines in the practice of an otolaryngologist presented by the candidate of medical sciences, head of the Kiev Scientific and Practical Centre of Endoscopic Rhinolaryngology, the honoured doctor of Ukraine Bol Bogdan Nazarovich, has aroused the great interest of the conference listeners.
In his speech, the speaker reported to the audience that the problem of allergic rhinitis is relevant not only in Ukraine, but throughout the world. According to the world literature, the number of patients suffering from allergic rhinitis exceeds 500 million people worldwide.
Allergic rhinitis often has a negative impact on the quality of life of patients. It disrupts daily activities and sleep resulting to deterioration in professional and social functioning.
Also, the speaker paid the attention to the issue of differential diagnosis of allergic and non-allergic rhinitis.
In the final part of his speech, Bogdan Nazarovich shared his experience of using the third generation antihistamine Tigofast.
According to the speaker the advantages of using Tigofast are as follows:
- High selectivity of action
- A pronounced anti-exudative and anti-inflammatory effect, providing a quick elimination of all symptoms of allergic rhinitis.
- Lack of metabolism in the liver, therefore minimal risk of drug interactions
- Lack of sedation.
In numerous studies, it has been proven that taking Tigofast has a minimal effect on the psychomotor function of patients. This makes it possible to use this drug for the treatment of allergic rhinitis in a wide range of patients, including drivers, pilots and people involved in mental activity.
Tigofast is recommended for symptomatic treatment of seasonal allergic rhinitis (Tigofast-120) and symptomatic treatment of chronic idiopathic urticaria (Tigofast-180) in adults and children over 12 years of age, 1 tablet once a day. The convenient method of administration ensures high adherence to treatment.
Tigofast - Your Allergy Protector!*
After Bogdan Nazarovich's report, Tigofast was awarded in the nomination “Optimal Compliance in the Choice of Antihistamine Therapy” by the President of the Association of Allergists of Ukraine, Sergey Zaykov.
On "Expert version" broadcasted online, the project experts Inna Gogunskaya (Allergologist, Doctor of Medical Sciences, Honoured Doctor of Ukraine, State Institution "O.S. Kolomiychenko Institute of Otolaryngology of NAMS of Ukraine") and Yulia Deyeva (Otorhinolaryngologist, Doctor of Medical Sciences, Professor, Head of the Chair of Otorhinolaryngology of Bogomolets National Medical University, expert of the Ministry of Health in the field of otolaryngology, paediatric otolaryngology, audiology) have conducted the diploma delivery ceremony "Optimal compliance in the choice of antihistamine therapy" of the drug Tigofast.
This event became a great opportunity for researchers and medical practitioners to exchange experience and knowledge, and to get acquainted with new achievements and promising directions in the treatment of various allergic diseases.
We invite you to listen to the report of Bol Bogdan Nazarovich on the website of the project "Expert version" at the following link
(start time of the report 1:48 min).
*More details about Tigofast can be found in the instructions for medical use.
Registration certificate No. UA/2730/01/02